Advertisement

Topics

Oxford Molecular Group Incorporated Company Profile

11:42 EDT 18th June 2018 | BioPortfolio

Oxford Molecular provides software tools and collaborative research services for identifying and optimizing drug candidates from biological targets. New automated technologies in genomics, high-throughput screening and combinatorial chemistry offer solutions for increasing the quantity and quality of pre-clinical drug candidates. Oxford Molecular helps companies to realize the benefits of these new technologies in the following areas:

Bioinformatics

Cheminformatics

Lead Optimization

Collaborative Research

Bioinformatics



Oxford Molecular is a leading supplier of software solutions for bioinformatics, including data services. Our bioinformatics products include the GCG Wisconsin Package™ and its two interfaces: SeqWeb™ for your web browser, and SeqLab® for X Windows. For the desktop, we offer OMIGA for Windows® and MacVector™ for the Macintosh. We also offer DataServe™, a convenient FTP service allowing pre-formatted downloads of public sequence databases. Finally, there is GENESEQ™ for comprehensive searching of patent sequences obtained from over 40 patent–issuing authorities worldwide.



New bioinformatics products include SeqStore™, which uses an Oracle® framework to integrate public, proprietary and in-house data across your company. Also new is OMIGA-GCG™, which enables users to search and retrieve sequence data from GCG Wisconsin Package databases and then perform sequence analysis within OMIGA’s Windows-based environment.



Cheminformatics



Oxford Molecular’s RS3 Discovery™ is an enterprise-wide research information solution using Oracle. RS3 manages the deluge of data from high-throughput screening and combinatorial chemistry synthesis. It can also assist in rapidly analyzing results and efficiently sharing verified data throughout the organization.



We also offer DIVA, an innovative visual tool for analyzing structures, properties and assay data. DIVA helps identify significant new entities from among thousands of compounds.



Oxford Molecular provides Chem-X™ for combinatorial library registration and lead generation. Its pharmacophore-based tools simplify library comparison and virtual screening.



Lead Optimization



Oxford Molecular helps scientists to discover relationships between molecular structure and activity, understand reactions and interactions between molecules, predict properties of new molecules, determine biological activity and assess toxicity—before expensive laboratory work is undertaken.



CAChe™ is a family of molecular modeling products for Macintosh and Windows desktop computers. Its award-winning user interface lets experimental chemists easily visualize molecules and reactions as well as predict and compare their chemical and physical properties.



For more sophisticated analysis, Oxford Molecular offers a suite of structure-activity programs for SGI workstations:



Tsar™ displays structures and properties in a spreadsheet form and performs a variety of statistical analyses. Tsar can also automatically substitute R-groups to define compounds.

Corina™ converts 2D structures to 3D.

Asp™ automatically aligns molecules for visual comparison.

Topkat® QSTRS provides quantitative assessment of toxicity from structure

Vamp™ performs semi-empirical quantum mechanics calculations to predict a variety of chemical and physical properties.

Collaborative Research



Oxford Molecular’s Collaborative Discovery division uses its expertise in informatics and drug design to accelerate the drug discovery process for clients in pharmaceutical and biotechnology companies. This expertise is complemented by the chemical synthesis skills of Cambridge Combinatorial and the advanced screening capabilities of Cambridge Drug Discovery. As a result, we are able to provide integrated, cost-effective solutions for target identification and validation, lead identification, and lead optimization.



Collaborative Discovery personnel have successfully managed and completed a wide range of multidisciplinary research collaborations. They bring together significant drug discovery experience in industry while also providing access to leading academic institutions through their relationships with key individuals. Our partners experience the benefits of new technologies while saving time and avoiding the cost of developing or supplementing internal resources.



Contact details



For further information, please contact Oxford Molecular:



Europe



Oxford Molecular Group PLC, Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK; tel: +44 1865 784600; fax: +44 1865 784601; web site http://www.oxmol.co.uk



US



Oxford Molecular Group, Inc., 2105 South Bascom Ave., Suite 200, Campbell, CA 95008, USA; tel: 1-408-879-6300 or 1-800-876-9994; fax: 1-408-879-6302; web site: http://www.oxmol.com

Location

2105 South Bascom Avenue Suite 200
Campbell
CA
95008
United States of America

Contact

Phone: 408 879 6300
Fax: 408 879 6302


News Articles [1249 Associated News Articles listed on BioPortfolio]

Oxford Blood Group

Below is a video introduction to the Oxford Blood Group, which encourages Patient and Public Involvement (PPI) with the Haematology and Stem Cells theme. Please contact oxfordbloodgroup@ouh.nhs.uk fo...

Oxford Gene Technology announces leadership changes

Oxford Gene Technology, The Molecular Genetics Company, has announced that on 1st April 2018 Dr John Anson who has been with the company since 2006 as EVP of R&D took over as CEO from Dr Mike Evans, w...

Oxford Centre for Haematology launched

The new Oxford Centre for Haematology has been launched with funding from the NIHR Oxford Biomedical Research Centre (BRC), bringing together University of Oxford researchers and clinicians from Oxfor...

Oxford Keeps Growing as a Hotspot for Cancer Vaccines with New Fundraising

Oxford Vacmedix has secured $12.5M (€10M) to start its first clinical trials, joining other Oxford-based biotechs in the cancer vaccine field such as Vaccitech and SpyBiotech. Oxford Vacmedix has s...

Cambridge Combinatorial Completes Collaboration With Dainippon Pharmaceutical; Expands Lab Facilities

Cambridge Combinatorial Ltd., a wholly owned subsidiary of Oxford Molecular Group, has completed delivery of library compounds in their collaboration with Dainippon Pharmaceutical Co. Ltd., a Japanese...

Dying for the group: What motivates the ultimate sacrifice?

(University of Oxford) Whether idolized as heroes or demonized and labelled terrorists, throughout history people have been willing to die for their groups and the causes they believe in. But why? New...

New haematology patient group launched

The launch of a new patient engagement group for those with blood conditions has brought together patients, clinicians and researchers to discuss how to get patient involved in research. A screening o...

Oxford Biomedica inks licensing agreement with Axovant Sciences

Gene and cell therapy group Oxford BioMedica has entered into an exclusive worldwide licensing agreement with Nasdaq-listed Axovant Sciences that will see the pair develop and commercialise OXB-102...

PubMed Articles [3745 Associated PubMed Articles listed on BioPortfolio]

Group Spike-and-Slab Lasso Generalized Linear Models for Disease Prediction and Associated Genes Detection by Incorporating Pathway Information.

Large-scale molecular data have been increasingly used as an important resource for prognostic prediction of diseases and detection of associated genes. However, standard approaches for omics data ana...

The Effect of End Group and Molecular Weight on the Yellowness of Polyetherimide.

The effects of end group and molecular weight on the yellowness of telechelic polyetherimide (PEI) are investigated. Electron-withdrawing dianhydride end groups reduce the yellowness and increase the ...

NGLview - Interactive molecular graphics for Jupyter notebooks.

NGLview is a Jupyter/IPython widget to interactively view molecular structures as well as trajectories from molecular dynamics simulations. Fast and scalable molecular graphics are provided through th...

pyHVis3D: Visualising Molecular Simulation deduced H-bond networks in 3D: Application to T-cell receptor interactions.

Hydrogen bonds (H-bonds) play an essential role for many molecular interactions but are also often transient, making visualizing them in a flexible system challenging.

Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.

Medulloblastoma, the most common malignant pediatric brain tumor, is a heterogeneous disease, with the existence of at least four molecular types: Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Gro...

Clinical Trials [5043 Associated Clinical Trials listed on BioPortfolio]

Oxford Partial Knee Replacement. A Randomized Clinical Trial of Three Implant Types

The purpose of this scientific study is to clarify whether there is a relationship between the appearance of radiolucent lines in bone-cement interphase of the tibial component of the diff...

Comparison of Oxford UKA and Sigma UKA With RSA.

Comparison of two unicompartmental knee arthroplasties (UKA), to see if Sigma UKA performs equally good as the Oxford UKA. The study focuses on how well the arthroplasty is fixated to the ...

A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System

The purpose of this study is to collect information on complications and survivorship of patients implanted with the Oxford™ Meniscal Unicompartmental Knee System at multiple sites in th...

Oxford® Partial Knee Kinematics Gait Analysis Study

The objective of this study is to compare the effect on gait of unicompartmental knee arthroplasty (UKA), using the Oxford® Partial Knee, versus total knee arthroplasty (TKA), using the V...

Evaluating Alternative Aftercare Models for Ex-offenders

This study is examining the relative effects of alternative aftercare models for ex-offenders who are recovering from substance abuse/addiction. The study is a longitudinal, randomized fie...

Companies [2587 Associated Companies listed on BioPortfolio]

Accelrys, Inc

The software businesses of the Oxford Molecular Group were incorporated into Accelrys Inc. on June 1, 2001.Oxford Molecular was a leading provider of cheminformatics tools. Founded in 1989, Oxford Mol...

Oxford BioMedica plc

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the...

Oxford Expression Technologies

Oxford Expression Technologies is a world-renowned centre of excellence for baculovirus protein expression. We provide protein expression products, services and consultancy to many global pharmaceutic...

Oxford Resource Partners, LP

Oxford Resource Partners, LP is a low cost producer of high value steam coal in Northern Appalachia and the Illinois Basin. Oxford markets its coal primarily to large electric utilities with coal-fir...

Oxford Healthcare Technology

Oxford Healthcare Technology is a staffing firm that leverages their recruiting expertise to deliver experienced healthcare professionals and project teams for consulting engageme...

More Information about "Oxford Molecular Group Incorporated" on BioPortfolio

We have published hundreds of Oxford Molecular Group Incorporated news stories on BioPortfolio along with dozens of Oxford Molecular Group Incorporated Clinical Trials and PubMed Articles about Oxford Molecular Group Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oxford Molecular Group Incorporated Companies in our database. You can also find out about relevant Oxford Molecular Group Incorporated Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record